当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Effectiveness of the monovalent rotavirus vaccine in Colombia: a case-control study.

Effectiveness of the monovalent rotavirus vaccine in Colombia: a case-control study.

Abstract：

OBJECTIVE:To assess the effectiveness of the monovalent rotavirus vaccine (RV1) to prevent rotavirus diarrhea admissions to emergency departments (ED) in Colombia. METHODS:A multicenter case-control study was carried out in six Colombian cities from 2011 to January, 2013. Cases were laboratory confirmed rotavirus diarrhea patients admitted to ED of selected health centers. Controls were patients with non-rotavirus diarrhea. Vaccination status was card-confirmed. Vaccine effectiveness and 95% confidence intervals (CI) were calculated from the conditional logistic regression models using the formula 1-adjusted odds ratio×100. RESULTS:1051 fecal samples were collected from 193 cases and 858 controls. Vaccination history was confirmed on 173 cases (90%) and 801 controls (93%). Among the rotavirus-positive samples with vaccination history, 57% were G2P[4], 9.8% G9P[8], 6% G9P[6]. Median age of cases (17 months) was greater than controls (15 months) (P<0.001), and mothers of cases had lower level of education (P=0.025). The adjusted effectiveness was 79.19% (95% CI, 23.7 to 94.32) among children 6-11 months of age and -39.75% (95% CI, -270.67 to 47.24) among those >12 months of age. Against overnight rotavirus hospitalizations, RV1 provided protection of 84.42% (95% CI, 22.68 to 96.86) among children 6-11 months of age, and -79.49% (95% CI, -555.8 to 51.08) among those >12 months. CONCLUSIONS:RV1 provided significant protection against rotavirus hospitalization among children under 1 year of age in the Colombian setting. The observation of lower effectiveness in children >12 months requires further assessment.

journal_name

Vaccine

journal_title

Vaccine

authors

Cotes-Cantillo K,Paternina-Caicedo A,Coronell-Rodríguez W,Alvis-Guzmán N,Parashar UD,Patel M,De la Hoz-Restrepo F

doi

10.1016/j.vaccine.2014.03.064

subject

Has Abstract

pub_date

2014-05-23 00:00:00

pages

3035-40

issue

25

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(14)00433-2

journal_volume

32

pub_type

杂志文章,多中心研究

相关文献

VACCINE文献大全
  • Efficacy study of a new albumin-free human diploid cell rabies vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients.

    abstract：:A newly developed human diploid cell rabies vaccine (Lyssavac-HDC), produced without added serum albumin and with an effort to remove the virus-inactivating beta-propriolactone prior to addition of the gelatin, L-cysteine and potassium phosphate stabilizer, was tested for safety immunogenicity, adverse reactions and e...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/0264-410x(94)00049-s

    authors： Wilde H,Glueck R,Khawplod P,Cryz SJ,Tantawichien T,Thipkong P,Chomchey P,Prakongsri S,Benjavongkulchai M,Sumboonanondha A

    更新日期：1995-04-01 00:00:00

  • Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

    abstract：:It has been known that influenza A virus infection induces a cross-protective immunity against infection by viruses with different subtypes of viral envelope proteins, hemagglutinin (HA) and neuraminidase (NA). This heterosubtypic immunity is generally mediated by cytotoxic T lymphocytes (CTL) reactive to specific epi...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(03)00234-2

    authors： Takada A,Matsushita S,Ninomiya A,Kawaoka Y,Kida H

    更新日期：2003-07-04 00:00:00

  • Development of dengue DNA vaccines.

    abstract：:Vaccination with plasmid DNA against infectious pathogens including dengue is an active area of investigation. By design, DNA vaccines are able to elicit both antibody responses and cellular immune responses capable of mediating long-term protection. Great technical improvements have been made in dengue DNA vaccine co...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2011.07.019

    authors： Danko JR,Beckett CG,Porter KR

    更新日期：2011-09-23 00:00:00

  • Is getting influenza vaccine coverage data out during mid-season feasible? Evidence from a national survey of U.S. adults.

    abstract：:We demonstrated the feasibility of collecting and disseminating mid-season estimates of influenza vaccine coverage. We surveyed a nationally representative sample of U.S. adults (n = 3972) via the Internet about use of influenza vaccination as of mid-November 2008. Findings were presented on 10 December 2008 to the me...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.04.007

    authors： Harris KM,Maurer J,Lurie N

    更新日期：2009-06-08 00:00:00

  • Using immunization delivery strategies to accelerate progress in Africa towards achieving the Millennium Development Goals.

    abstract：:Integration of health services brings together common functions within and between organizations to solve common problems, developing a commitment to a shared vision and goals, and using common technologies and resources to achieve these goals. Integration has been the frustrated rally call of Primary Health Care for ...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2008.02.032

    authors： Clements CJ,Nshimirimanda D,Gasasira A

    更新日期：2008-04-07 00:00:00

  • Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran.

    abstract：BACKGROUND:Although the mortality from diarrheal diseases has been decreasing dramatically in Iran, it still represents an important proportion of disease burden in children <5 years old. Rotavirus vaccines are among the most effective strategies against diarrheal diseases in specific epidemiological conditions. This s...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.12.035

    authors： Javanbakht M,Moradi-Lakeh M,Yaghoubi M,Esteghamati A,Mansour Ghanaie R,Mahmoudi S,Shamshiri AR,Zahraei SM,Baxter L,Shakerian S,Chaudhri I,Fleming JA,Munier A,Baradaran HR

    更新日期：2015-05-07 00:00:00

  • Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity.

    abstract：:A novel recombinant hepatitis B vaccine, trademarked Sci-B-Vac, was evaluated for safety, tolerability and immunogenicity in an open label trial performed in Singapore. The experimental vaccine, derived from Chinese hamster ovary (CHO) cells, consists of hepatitis B surface antigen (HBsAg) particles harbouring all thr...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1016/0264-410x(92)90391-v

    authors： Yap I,Guan R,Chan SH

    更新日期：1992-01-01 00:00:00

  • Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination.

    abstract：:Age-specific force of varicella infection, hospitalisation and death rates in non-immune persons were calculated using an age-based mathematical model and national data for France. A cost-effectiveness model was then applied to hypothetical cohorts of persons aged 15-45 years with a negative or uncertain history of va...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(03)00405-5

    authors： Hanslik T,Boëlle PY,Schwarzinger M,Carrat F,Freedberg KA,Valleron AJ,Flahault A

    更新日期：2003-09-08 00:00:00

  • Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection.

    abstract：:Efficacy studies of investigational HIV vaccines require enrollment of individuals at 'high risk' for HIV. This paper examines participation in HIV vaccine trials among women at 'high risk' for HIV acquisition. In-depth interviews were conducted with 17 African-American women who use crack cocaine and/or exchange sex ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.06.064

    authors： Voytek CD,Jones KT,Metzger DS

    更新日期：2011-08-18 00:00:00

  • Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study.

    abstract：INTRODUCTION:We estimated influenza vaccine effectiveness (IVE) to prevent laboratory-confirmed influenza-related hospitalizations in patients 18 years old or older during the 2010-2011 influenza season. METHODS:We conducted a prospective case-control study in five hospitals, in Valencia, Spain. Study subjects were co...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.vaccine.2012.07.006

    authors： Puig-Barberà J,Díez-Domingo J,Arnedo-Pena A,Ruiz-García M,Pérez-Vilar S,Micó-Esparza JL,Belenguer-Varea A,Carratalá-Munuera C,Gil-Guillén V,Schwarz-Chavarri H

    更新日期：2012-08-24 00:00:00

  • HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis.

    abstract：INTRODUCTION:We performed a pooled analysis of randomised clinical trials (RCT) on HPV vaccine efficacy in preventing cervical persistent infection. METHODS:We carried out a bibliographic search on electronic databases and we selected RCT to perform the meta-analyses. RESULTS:We selected five studies. The first meta-...

    journal_title：Vaccine

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.vaccine.2007.09.027

    authors： La Torre G,de Waure C,Chiaradia G,Mannocci A,Ricciardi W

    更新日期：2007-12-05 00:00:00

  • Evaluation of adverse effects of vaccines: the case-control approach.

    abstract：:When the hypothesis of a link between vaccination and a possible adverse outcome arises, further investigation is required to confirm or refute the suspicion. Given the rarity of most serious adverse effects, a case-control approach will often be chosen. This paper discusses aspects of the design, analysis and interpr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(02)00147-0

    authors： Smeeth L,Rodrigues LC,Hall AJ,Fombonne E,Smith PG

    更新日期：2002-06-07 00:00:00

  • Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.

    abstract：:Pfs25, a Plasmodium falciparum surface protein expressed during zygote and ookinete stages in infected mosquitoes, is a lead transmission-blocking vaccine candidate against falciparum malaria. To enhance immunogenicity, recombinant Pfs25 was chemically conjugated to recombinant nontoxic Pseudomonas aeruginosa ExoProte...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.04.067

    authors： Zhu D,Wu Y,McClellan H,Dai W,Rausch K,Jones D,Aebig J,Barnafo E,Butler B,Lambert L,Narum DL,Duffy PE

    更新日期：2017-05-31 00:00:00

  • Vaccination of pigs with a recombinant porcine adenovirus expressing the gD gene from pseudorabies virus.

    abstract：:Five week old, commercially available large white pigs were vaccinated with either a single dose or two doses of a recombinant porcine adenovirus expressing the glycoprotein D gene from pseudorabies virus (PRV). Pigs were monitored for the development of serum neutralizing antibodies to PRV and challenged 3 weeks afte...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00084-6

    authors： Hammond JM,Jansen ES,Morrissy CJ,van der Heide B,Goff WV,Williamson MM,Hooper PT,Babiuk LA,Tikoo SK,Johnson MA

    更新日期：2001-06-14 00:00:00

  • Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.

    abstract：BACKGROUND:Alternative methods for influenza vaccine production are needed to ensure adequate supplies. METHODS:Healthy adults 50-64 years were assigned randomly to receive one intramuscular injection of trivalent recombinant hemagglutinin (rHA) or U.S. licensed trivalent inactivated vaccine (TIV) containing H1, H3 an...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.vaccine.2011.01.039

    authors： Baxter R,Patriarca PA,Ensor K,Izikson R,Goldenthal KL,Cox MM

    更新日期：2011-03-09 00:00:00

  • Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge.

    abstract：:Ebola virus (EBOV) is among the deadliest pathogens known to man causing infrequent outbreaks of hemorrhagic disease. In humans, the case fatality rates in the outbreaks can reach 90%. During the West African epidemic almost 30,000 people were infected and of these over 11,000 fatalities were reported. Currently, we a...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.06.035

    authors： Lehrer AT,Wong TS,Lieberman MM,Johns L,Medina L,Feldmann F,Feldmann H,Marzi A

    更新日期：2019-11-08 00:00:00

  • E-health use, vaccination knowledge and perception of own risk: drivers of vaccination uptake in medical students.

    abstract：OBJECTIVE:was to improve understanding of mechanisms contributing to healthcare personnel's (HCP) reluctance to get vaccinated against seasonal influenza. We assessed the role of several drivers: vaccination knowledge, vaccination recommendations and the role of the Internet (so-called e-health) in creating vaccination...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.12.021

    authors： Betsch C,Wicker S

    更新日期：2012-02-01 00:00:00

  • Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity.

    abstract：INTRODUCTION:The World Health Organization recommends that as part of the polio end-game strategy a dose of inactivated poliovirus vaccine (IPV) be introduced by the end of 2015 in all countries currently using only oral poliovirus vaccine (OPV). Administration of fractional dose (1/5 of full dose) IPV (fIPV) by intrad...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2015.06.071

    authors： Resik S,Tejeda A,Mach O,Sein C,Molodecky N,Jarrahian C,Saganic L,Zehrung D,Fonseca M,Diaz M,Alemany N,Garcia G,Hung LH,Martinez Y,Sutter RW

    更新日期：2015-10-26 00:00:00

  • The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates.

    abstract：:In a previous work we selected montanide ISA720 (M-ISA720) among different adjuvants for the vaccination with a V3 loop based multi-epitope polypeptide TAB9. In this paper we present the evaluation of the toxicity and immunogenicity of this formulation in non-human primates. TAB9 in M-ISA720 was highly immunogenic in ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00358-2

    authors： Gómez CE,Navea L,Lobaina L,Dubed M,Expósito N,Soto A,Duarte CA

    更新日期：1999-05-04 00:00:00

  • The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies.

    abstract：:Respiratory syncytial virus (RSV) causes severe respiratory illness in infants. There are no licensed vaccines to prevent RSV infection. The neonate receives short-term protection from maternally derived antibodies, which, however, can also interfere with the active response to vaccination. A RSV vaccine consisting of...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.01.041

    authors： Garg R,Latimer L,Gerdts V,Potter A,van Drunen Littel-van den Hurk S

    更新日期：2015-03-10 00:00:00

  • A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.

    abstract：:In this study, a recombinant truncated West Nile virus envelope protein antigen (rWNV-E) was produced in serum-free cultures of the expresSF+ insect cell line via baculovirus infection. This production system was selected based on its use in the production of candidate human and animal vaccine antigens. A defined ferm...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.10.046

    authors： Bonafé N,Rininger JA,Chubet RG,Foellmer HG,Fader S,Anderson JF,Bushmich SL,Anthony K,Ledizet M,Fikrig E,Koski RA,Kaplan P

    更新日期：2009-01-07 00:00:00

  • A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.

    abstract：:Pneumococcal and Salmonella typhi infections are two major diseases for children in developing countries. For typhoid fever, licensed Vi polysaccharide vaccines are ineffective in children <2-year old. While investigational Vi conjugate vaccines have been shown effective in clinical trials, they are currently only ava...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.03.039

    authors： Lu YJ,Zhang F,Sayeed S,Thompson CM,Szu S,Anderson PW,Malley R

    更新日期：2012-05-14 00:00:00

  • Surveillance of congenital rubella syndrome in Japan, 1978-2002: effect of revision of the immunization law.

    abstract：:Infection of rubella virus at the early stages of pregnancy in women who are not immune to rubella often induces congenital anomalies in infants, namely congenital rubella syndrome (CRS). This paper is the first comprehensive report of CRS cases in Japan, compiled from a questionnaire to major hospitals, reports to jo...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.03.055

    authors： Katow S

    更新日期：2004-09-28 00:00:00

  • rOmpF and OMVs as efficient subunit vaccines against Salmonella enterica serovar Enteritidis infections in poultry farms.

    abstract：:Salmonella enterica serovar Enteritidis remains the most prevalent serotype causing human salmonellosis through the consumption of contaminated foods, especially poultry products. The development of a subunit vaccine against S. Enteritidis can not only protect chickens against Salmonella infection in the poultry indus...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.08.074

    authors： Li Q,Ren J,Xian H,Yin C,Yuan Y,Li Y,Ji R,Chu C,Qiao Z,Jiao X

    更新日期：2020-10-21 00:00:00

  • Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine.

    abstract：:We successfully re-vaccinated hepatitis B virus (HBV) vaccine non-responders using a double dose of the combined hepatitis A virus (HAV) and HBV vaccine. The hope was to improve priming of hepatitis B surface antigen (HBsAg)-specific cell mediated immune response (CMI) by an increased antigen dose and a theoretical ad...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.08.054

    authors： Nyström J,Cardell K,Björnsdottir TB,Fryden A,Hultgren C,Sällberg M

    更新日期：2008-11-05 00:00:00

  • A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial.

    abstract：:The co-administration of the tetravalent meningococcal conjugate vaccine, MenACWY-TT, with a licensed hepatitis A and B vaccine, HepA/B (Twinrix(®)), was compared to their separate administration in this open, randomised, controlled study. Healthy subjects 11-17 years of age (n=611) were randomised (3:1:1) to receive ...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2011.11.051

    authors： Østergaard L,Silfverdal SA,Berglund J,Flodmark CE,West C,Bianco V,Baine Y,Miller JM

    更新日期：2012-01-17 00:00:00

  • Basic principle of population-based cohort study to evaluate influenza vaccine effectiveness among elderly Japanese.

    abstract：:Influenza vaccines minimize the risk of influenza-related morbidity, complication, and death in elderly people. Although evaluating vaccine effectiveness (VE) is important for promoting immunization programs and coping with influenza epidemics, it is difficult to evaluate its effectiveness in Japan, where no framework...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.07.002

    authors： Hara M,Hirota Y

    更新日期：2017-08-24 00:00:00

  • Effect of thiomersal on dissociation of intact (146S) foot-and-mouth disease virions into 12S particles as assessed by novel ELISAs specific for either 146S or 12S particles.

    abstract：:Intact (146S) foot-and-mouth disease virions (FMDVs) can dissociate into specific (12S) viral capsid degradation products. Using two single-domain antibody fragments that bind specifically to either 146S or 12S particles we developed two ELISAs for the quantification of these particles in FMDV antigen preparations use...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.01.069

    authors： Harmsen MM,Fijten HP,Westra DF,Coco-Martin JM

    更新日期：2011-03-24 00:00:00

  • Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.

    abstract：:Chagas' disease is a major tropical disease for which a cure for chronic phase does not exist yet. Trypanosoma cruzi trans-sialidase (TS) seems to be involved in relevant processes such as infectivity, host survival and, very importantly, disease pathogenesis. In this study, we show that mice vaccinated with an engine...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.02.060

    authors： Fontanella GH,De Vusser K,Laroy W,Daurelio L,Nocito AL,Revelli S,Contreras R

    更新日期：2008-05-02 00:00:00

  • Safety of Zostavax™--a cohort study in a managed care organization.

    abstract：BACKGROUND:Zostavax™ is a live, attenuated varicella-zoster virus vaccine indicated for the prevention of herpes zoster (shingles). An observational post-licensure (Phase IV) study was conducted at Kaiser Permanente Northern California (KPNC), a US managed care organization, to assess the safety of zoster vaccine in pe...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.08.070

    authors： Baxter R,Tran TN,Hansen J,Emery M,Fireman B,Bartlett J,Lewis N,Saddier P

    更新日期：2012-10-19 00:00:00